文献速递淋巴瘤

来那度胺联合CHOEP作为II-IV期外周T细胞淋巴瘤初始治疗的II期研究最终结果

Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.
PubMed 文献 · Br J Haematol · 2023-05-22

该II期研究评估来那度胺联合CHOEP方案治疗II-IV期外周T细胞淋巴瘤的疗效与安全性。39例可评估患者中,6周期后客观缓解率69%,完全缓解率49%,部分缓解率21%,疾病进展率13%。32例(82%)完成全诱导,7例(18%)因毒性终止,主要为血液学毒性;中位随访21.3个月,2年无进展生存率55%(95%CI 37%-70%),总生存率78%(95%CI 59%-89%)。

要点

  • 6周期来那度胺联合CHOEP的客观缓解率为69%,完全缓解率为49%。
  • 32例(82%)完成全诱导,7例(18%)因毒性终止,主要为血液学毒性。
  • 3或4级发热性中性粒细胞减少发生率为35%,尽管使用了强制性生长因子。

核心结论

  • 6周期来那度胺联合CHOEP的缓解率有限,主要归因于血液学毒性,该毒性导致并非所有患者均能完成计划诱导。

研究设计与样本

  • II期研究,评估来那度胺联合CHOEP作为淋巴结型外周T细胞淋巴瘤的新型诱导策略。
  • 患者接受标准剂量CHOEP联合来那度胺10 mg(每21天周期第1-10天给药),共6周期。
  • 6周期后按提供者偏好选择观察、大剂量治疗联合自体干细胞 rescue 或来那度胺维持。
  • 39例患者可评估疗效。

主要发现

  • 39例可评估患者中,6周期后客观缓解率为69%,完全缓解率为49%,部分缓解率为21%,疾病稳定率为0%,疾病进展率为13%。
  • 32例患者(82%)完成全诱导,7例患者(18%)因毒性终止,主要为血液学毒性。
  • 任何级别血液学毒性发生于超过50%的患者,3或4级发热性中性粒细胞减少发生于35%的患者,尽管使用了强制性生长因子。
  • 存活患者中位随访21.3个月,估计2年无进展生存率为55%(95%CI 37%-70%),总生存率为78%(95%CI 59%-89%)。

关键数值与推荐

  • 来那度胺剂量为10 mg,每21天周期第1-10天给药,联合标准剂量CHOEP,共6周期。
  • 6周期后客观缓解率69%,完全缓解率49%,部分缓解率21%,疾病稳定率0%,疾病进展率13%。
  • 2年无进展生存率55%(95%CI 37%-70%),2年总生存率78%(95%CI 59%-89%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There remains no one standard induction for nodal-based peripheral T-cell lymphoma (PTCL). We conducted a phase II study of lenalidomide plus CHOEP as a novel induction strategy. Patients received CHOEP at standard doses in combination with 10 mg of lenalidomide on days 1-10 of a 21-day cycle for six cycles of therapy followed by observation, high-dose therapy with autologous stem cell rescue, or maintenance lenalidomide per provider preference. Among 39 patients evaluable for efficacy, the objective response rate after six cycles was 69%, with complete response in 49%, partial response in 21%, stable disease in 0% and progressive disease in 13%. Thirty-two patients (82%) completed full induction, and seven patients (18%) discontinued for toxicity, primarily hematologic. Any grade hematologic toxicity occurred in over 50% of patients, with grade 3 or 4 febrile neutropenia occurring in 35% of patients despite mandated growth factors. With a median followup of surviving patients of 21.3 months, the estimated 2-year progression-free and overall survival were 55% (95% CI 37%-70%) and 78% (95% CI 59%-89%), respectively. In sum, six cycles of lenalidomide plus CHOEP resulted in a modest response rate primarily due to hematologic toxicity, which prevented all patients from completing planned induction.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Stuver R, Horwitz SM, Advani RH, et al. Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma. Br J Haematol. 2023. PMID: 37217196. doi:10.1111/bjh.18885

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。